Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LOXL2 | Q9Y4K0 | 1/20 | 0.68 |
| ▸ | CYP4F2 | P78329 | 2/20 | 0.66 |
| ▸ | CYP4A11 | Q02928 | 2/20 | 0.66 |
| ▸ | SLC7A5 | Q01650 | 1/20 | 0.57 |
| ▸ | MRGPRX4 | Q96LA9 | 2/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.52 |
| ▸ | RAB9A | P51151 | 2/20 | 0.52 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.52 |
| ▸ | MAPT | P10636 | 1/20 | 0.52 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.52 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.51 |
| ▸ | TSHR | P16473 | 1/20 | 0.50 |
| ▸ | FOLH1 | Q04609 | 1/20 | 0.50 |
| ▸ | HPGD | P15428 | 1/20 | 0.50 |
| ▸ | MEN1 | O00255 | 1/20 | 0.49 |
| ▸ | NPC1 | O15118 | 1/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.49 |
| ▸ | ERN1 | O75460 | 1/20 | 0.49 |
| ▸ | HCRTR1 | O43613 | 1/20 | 0.49 |
| ▸ | HCRTR2 | O43614 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL757447 | 0.87 | LOXL2 (0.64) | LOXL2CYP4F2CYP4A11SLC7A5MRGPRX4 | |
| SCHEMBL4682498 | 0.85 | LOXL2 (0.67) | LOXL2CYP4F2CYP4A11SLC7A5MRGPRX4 | |
| SCHEMBL9623658 | 0.85 | CYP4F2 (0.69) | LOXL2CYP4F2CYP4A11SLC7A5MRGPRX4 | |
| SCHEMBL21579366 | 0.84 | LOXL2 (0.70) | LOXL2CYP4F2CYP4A11SLC7A5MRGPRX4 | |
| SCHEMBL8367820 | 0.84 | LOXL2 (0.60) | LOXL2CYP4F2CYP4A11SLC7A5MRGPRX4 | |
| SCHEMBL126284 | 0.84 | LOXL2 (0.74) | LOXL2CYP4F2CYP4A11SLC7A5MRGPRX4 | |
| SCHEMBL70173 | 0.84 | CYP4F2 (0.83) | LOXL2CYP4F2CYP4A11SLC7A5MRGPRX4 | |
| SCHEMBL31752875 | 0.83 | CYP4A11 (0.69) | LOXL2CYP4F2CYP4A11SLC7A5MRGPRX4 | |
| SCHEMBL8710710 | 0.83 | LOXL2 (0.59) | LOXL2CYP4F2CYP4A11SLC7A5MRGPRX4 | |
| SCHEMBL13601337 | 0.83 | LOXL2 (0.59) | LOXL2CYP4F2CYP4A11SLC7A5MRGPRX4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 70 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240124447-A1 | INHIBITORS OF THE MENIN-MLL INTERACTION | VITAE PHARMACEUTICALS, LLC (US) | 2024-04-18 | — | — | US | disclosed |
| US-11739085-B2 | Inhibitors of the menin-MLL interaction | VITAE PHARMACEUTICALS, LLC (US) | 2023-08-29 | — | — | US | disclosed |
| EP-4230627-A2 | INHIBITORS OF THE MENIN-MLL INTERACTION | Vitae Pharmaceuticals, LLC (US) | 2023-08-23 | — | — | EP | disclosed |
| EP-3512850-B1 | INHIBITORS OF THE MENIN-MLL INTERACTION | VITAE PHARMACEUTICALS LLC (US) | 2023-04-12 | — | — | EP | disclosed |
| CN-115260165-A | Benzo nitrogen-containing five-membered heterocyclic compound and synthesis and application thereof | 中国科学院上海药物研究所 | 2022-11-01 | — | — | CN | disclosed |
| US-20210179611-A1 | INHIBITORS OF THE MENIN-MLL INTERACTION | VITAE PHARMACEUTICALS, LLC (US) | 2021-06-17 | — | — | US | disclosed |
| US-20210024493-A1 | Diamide Compounds Having Muscarinic Receptor Antagonist and Beta2 Adrenergic Receptor Agonist Activity | THERAVANCE RESPIRATORY COMPANY, LLC | 2021-01-28 | — | — | US | disclosed |
| US-10899758-B2 | Inhibitors of the menin-MLL interaction | VITAE PHARMACEUTICALS, LLC (US) | 2021-01-26 | — | — | US | disclosed |
| US-10836744-B2 | Diamide compounds having muscarinic receptor antagonist and β2 adrenergic receptor agonist activity | THERAVANCE RESPIRATORY COMPANY, LLC (US) | 2020-11-17 | — | — | US | disclosed |
| US-20200165223-A1 | Diamide Compounds Having Muscarinic Receptor Antagonist and Beta2 Adrenergic Receptor Agonist Activity | THERAVANCE RESPIRATORY COMPANY, LLC | 2020-05-28 | — | — | US | disclosed |
| EP-1646608-A1 | TRICYCLIC DERIVATIVES OR PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF, THEIR PREPARATIONS AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | JE IL Pharmaceutical Co., Ltd. (KR) | 2006-04-19 | — | — | EP | disclosed |
| WO-2004113281-A1 | TRICYCLIC DERIVATIVES OR PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF, THEIR PREPARATIONS AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | JE IL PHARMACEUTICAL CO., LTD. (KR) | 2004-12-29 | — | — | WO | disclosed |
| EP-0695741-B1 | 7-THIAPROSTAGLANDINS AND PROCESS FOR PRODUCING THE SAME | TEIJIN LTD (JP) | 2004-06-16 | — | — | EP | disclosed |
| US-5731452-A | 7-thiaprostaglandins and method of production thereof | TEIJIN LIMITED (JP) | 1998-03-24 | — | — | US | disclosed |
| EP-0695741-A1 | 7-THIAPROSTAGLANDINS AND PROCESS FOR PRODUCING THE SAME | TEIJIN LIMITED (JP) | 1996-02-07 | — | — | EP | disclosed |
| EP-0399818-B1 | Diarylstyrylquinoline diacids | MERCK FROSST CANADA INC (CA) | 1995-08-16 | — | — | EP | disclosed |
| US-5204358-A | Antiallergens; antiinflammatory agents; treatment of asthma, rhinitis, bronchitis and skin diseases | MERCK FROSST CANADA, INC. (CA) | 1993-04-20 | — | — | US | disclosed |
| US-5104882-A | Leukotriene antagonists | MERCK FROSST CANADA, INC. (CA) | 1992-04-14 | — | — | US | disclosed |
| EP-0399818-A1 | Diarylstyrylquinoline diacids | MERCK FROSST CANADA INC. (CA) | 1990-11-28 | — | — | EP | disclosed |
| EP-0318093-A2 | Diarylquinoline diacids and their use as medicaments | MERCK FROSST CANADA INC. (CA) | 1989-05-31 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10836744-B2 | Diamide compounds having muscarinic receptor antagonist and β2 adrenergic receptor agonist activity | ADRB2, ADRB1, ADRA2A | LOXL2 3068/4885CYP4F2 1433/4885CYP4A11 1100/4885 |
| US-20210024493-A1 | Diamide Compounds Having Muscarinic Receptor Antagonist and Beta2 Adrenergic Receptor Agonist Activity | ADRB2, ADRB1, ADRA2B | LOXL2 1632/4885CYP4F2 2223/4885CYP4A11 751/4885 |
| US-11739085-B2 | Inhibitors of the menin-MLL interaction | MLLT1, MEN1, MLLT3 | LOXL2 3164/4885CYP4F2 2982/4885CYP4A11 3857/4885 |
| US-10899758-B2 | Inhibitors of the menin-MLL interaction | MLLT1, MEN1, MLLT3 | LOXL2 3164/4885CYP4F2 2982/4885CYP4A11 3857/4885 |
| US-20240124447-A1 | INHIBITORS OF THE MENIN-MLL INTERACTION | MLLT1, MEN1, MLLT3 | LOXL2 3164/4885CYP4F2 2982/4885CYP4A11 3857/4885 |
| US-20200165223-A1 | Diamide Compounds Having Muscarinic Receptor Antagonist and Beta2 Adrenergic Receptor Agonist Activity | ADRB2, ADRB1, ADRA2B | LOXL2 3359/4885CYP4F2 1554/4885CYP4A11 1051/4885 |
| US-20210179611-A1 | INHIBITORS OF THE MENIN-MLL INTERACTION | MLLT1, MEN1, MLLT3 | LOXL2 3164/4885CYP4F2 2982/4885CYP4A11 3857/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.